Souhaitez-vous accéder aux communiqués récents ?

FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name BrexafemmeTM, and granted priority review...

New York, March 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Animal Biotechnology Market Research Report by Product, by Application - Global Forecast to 2025 -...

Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal...

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...

Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while...

New York, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Animal Biotechnology Market Research Report by Product, by Application - Global Forecast to 2025 -...

Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of...

WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...

Dublin, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The "Candidemia - Market Insights, Epidemiology, and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The...

JERSEY CITY, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded...